The hope and reality of long‐acting hemophilia products

Abstract excerpt

Recombinant DNA technology and protein engineering are creating hope that we can address ongoing challenges in hemophilia care such as reducing the costs of therapy, increasing the availability to the developing world, and improving the functional properties of these proteins. Technological advances to improve the half-life of recombinant clotting factors have brought long-acting clotting factors for hemophilia...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cancer-related gene regulation
• Share to Hemophilia Treatment and Research
• Share to Platelet Disorders and Treatments